Please login to the form below

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

Novartis builds its case for novel MS treatment ofatumumab

That competition paves the way for new entries, including Novartis’ ofatumumab and Bristol-Myers Squibb’s oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod which is also currently under review with

Latest news

BMS suspends new clinical trials as COVID-19 cases rise in US

That includes an FDA decision on multiple sclerosis therapy ozanimod, which was due yesterday, and a verdict due by 4 April for Reblozyl (luspatercept) as a second-line therapy for anaemia
J&J aims for US approval of MS drug ponesimod

Bristol-Myers Squibb may also possess a potential rival, as it is due for an FDA decision on its MS drug ozanimod soon, following a series of delays due to the
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS share price up by 3% on the back of results
Biogen’s R&D chief Ehlers heads for the exit

Biogen is heavily reliant on its wider MS portfolio, and a slew of newly launched or anticipated rival therapies like Novartis’ Mayzent (ozanimod) and Roche’s Ocrevus (ocelizumab) are already threatening
J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Also coming through the pipeline is Biogen’s Tecfidera follow-up diroximel fumarate (BIIB098), Novartis’ new antibody ofatumumab, and Celgene’s S1P receptor modulator ozanimod that is due for regulatory decision

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the
20 for 2020 – Five pharma companies to watch

treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
Pharma deals in July 2015

Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...